VRAX (VRAX) Stock Price & Analysis
VRAX (VRAX) fell 9.87% to USD 0.19 as of June 10, 2026 at 02:13 UTC, according to Nexqual real-time market data.
VRAX last closed at USD 0.21; the session ranged USD 0.17–0.2 on volume of 1,230,584 shares. Market capitalization is $1.40M, with a 52-week range of USD 0.1–1.14 (NCM). Source: Nexqual, June 10, 2026 at 02:13 UTC.
Key Statistics (as of June 10, 2026 at 02:13 UTC)
| Price | USD 0.19 |
|---|---|
| Change | ▼ 9.87% (down) |
| Previous Close | USD 0.21 |
| Open | USD 0.19 |
| Day Range | USD 0.17 – 0.2 |
| 52-Week Range | USD 0.1 – 1.14 |
| Volume | 1,230,584 shares |
| Market Cap | $1.40M |
| Exchange | NCM |
Technical Analysis (VRAX)
Nexqual's technical model rates VRAX "NEUTRAL" based on 3 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:13 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.25 (neutral) |
| vs SMA50 | Above (USD 0.18) |
| MACD | 0.01 (positive) |
Analyst Ratings (VRAX)
Wall Street analysts rate VRAX "None" based on 1 analysts, with a mean price target of USD 1 (range USD 1–1), per Nexqual as of June 10, 2026 at 02:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 1 |
| High Target | USD 1 |
| Low Target | USD 1 |
Earnings (VRAX)
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financials & Fundamentals (VRAX)
| Total Revenue | $2,986 |
|---|---|
| Revenue Growth (YoY) | -67.50% |
| Gross Margin | +0.00% |
| Operating Margin | -160788.32% |
| Profit Margin | +0.00% |
| ROE | -83.82% |
| Debt / Equity | 10.6 |
| Current Ratio | 11.35 |
| Total Cash | $3.44M |
| Total Debt | $537,993 |
| Free Cash Flow | $-3.54M |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financial Health Score (VRAX)
Nexqual rates VRAX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:13 UTC.
| Growth | Critical — Revenue -68% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -84%, ROA -48.4% |
Ownership (VRAX)
| Insider Ownership | +1.79% |
|---|---|
| Institutional Ownership | +4.62% |
| Shares Outstanding | 7.42M |
| Float | 5.98M |
| Short % of Float | +15.30% |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Leadership (VRAX)
VRAX is led by James Foster (age 40), Chairman, CEO & Principal Accounting Officer, per Nexqual as of June 10, 2026 at 02:13 UTC.
| Chairman, CEO & Principal Accounting Officer | James Foster (age 40) |
|---|---|
| COO & Director | Nigel McCracken M.Sc. (age 60) |
Major Backers & Investors (VRAX)
Notable institutional backers of VRAX include Armistice Capital, LLC, Jump Financial, LLC, according to Nexqual as of June 10, 2026 at 02:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 20.24% |
| Jump Financial, LLC | 0.94% |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| ILAG | Intelligent Living Application | USD 3.73 | ▲ 6.57% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| SOBR | SOBR Safe, Inc. | USD 0.75 | ▼ 26.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:13 UTC. This page is informational and not investment advice.